Skip to main content
Tech.euFundingExplorerBeta

iOnctura

iOnctura operates as a clinical-stage biotechnology company that specializes in developing a treatment for cancer.

iOnctura has raised €113M across 4 funding rounds from 10 investors, most recently a Series B round in Jun 2024. Based in Geneva, Switzerland; founded 2017; active in Healthtech. Data as of 28 Oct 2026.

Geneva, SwitzerlandFounded 2017ionctura.com ↗
Healthtech
← All companies
Total raised
€113M
€112,913,052
Funding rounds
4
Investors
10
distinct backers
Active since
2020-01
latest 2024-06

Funding by year

EUR raised per year
iOnctura — funding by year — interactive chart.
Data table
iOnctura — funding by year
2020€15M
2022€18M
2024€80M

Signals

High confidence
Raise-next likelihood42
base rate 48% for Series B
  • ▼ In typical raise window
  • ▲ Up-round momentum
  • ▼ Low backer re-investment
Exit likelihood14
base rate 11% (2+ rounds)
  • ▲ €100M+ raised
  • ▲ 4 rounds raised
  • ▲ 9y since founding (typical exit age)
  • ▼ No recent equity round (debt-only or quiet)

Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

4 rounds
DateStageAmountInvestors
2024-06-24Series B€80M3B Future Health Fund,EIC Fund,INKEF Capital,M Ventures,Schroders Capital,Syncona Partners+1 moreView deal →
2022-12-21Other€18MEIC AcceleratorView deal →
2022-09-22Seed€413kFongit Innovation Fund (FIF)View deal →
2020-01-23Series A€15MINKEF Capital,VI PartnersView deal →

Investors

10
3B Future Health FundEIC AcceleratorEIC FundFongit Innovation Fund (FIF)INKEF CapitalM VenturesSchroders CapitalSyncona PartnersVI Partners

Related news

Similar companies

same sector or country

Global coverage: FundingData